| Name | Title | Contact Details |
|---|---|---|
Rakesh Surve |
Director, Information Security and Services | Profile |
AcelRx Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. The Company`s product candidates, DSUVIA™ (known as ARX-04 outside of the United States) and ZALVISO®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. DSUVIA is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. The Phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. In clinical studies, DSUVIA demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and vomiting. A New Drug Application (NDA) was filed with the FDA in December 2016. ZALVISO is designed to deliver sublingual tablets containing 15 mcg sufentanil via a novel hand-held, pre-programmed, patient-controlled analgesia system. Three Phase 3 clinical trials have been completed in patients who had undergone major abdominal or orthopedic surgeries. A fourth study (IAP312) is underway to further evaluate the overall performance of the ZALVISO System in post-surgical patients. ZALVISO is currently approved by the European Commission for the management of acute moderate-to-severe post-operative pain in adult patients in a hospital setting, and is marketed by Grünenthal Group, AcelRx`s licensee in Europe and Australia. In the United States and other geographies, ZALVISO remains an investigational product.
SouthStar Health Group is a Atlanta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Comprehensive Alcoholism Treatment Program is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Humco Holding Group, Inc. is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Humco Holding Group, Inc. is based in Texarkana, TX. You can find more information on Humco Holding Group, Inc. at www.humco.com
Sarah Bush Lincoln Health Center is a 129-bed, not-for-profit, regional hospital centrally located in East Central Illinois Coles County, and is the recipient of the 2011 Illinois Performance Excellence Gold Award for Achievement of Excellence, the highest performance honors in the state. Sarah Bush Lincoln is accredited by The Joint Commission, the nations oldest and largest standards-setting and accrediting body in healthcare. The Health Center provides a full range of acute care services to residents of Coles County and the surrounding eight counties. Home health services extend to the surroundings 19 counties in East Central and Southern Illinois. Active and consulting medical staffs include approximately 175 providers representing 28 specialties. Some of the services provided by the Health Center include: a Regional Cancer Center, a Heart Center with Cardiac Catheterization and Rehabilitation in partnership with Prairie Heart Institute of Illinois, a Surgery Center, Women & Childrens Services, a Level II Perinatal Unit, Medical-Surgical units, Behavioral Health Services, Close Observation Unit, a Sleep Disorders Center, Diagnostic Imaging Services, and Laboratory. Outreach services include a durable medical company (Lincolnland Home Medical Equipment), a Reference Laboratory, Peace Meal, Lincolnland Home Health and Hospice, Lifeline, and Lincolnland Homemakers. Sarah Bush Lincoln has 14 extended campus primary care locations and three walk-in clinics. Employing about 2,350 area residents, the Health Center promotes a culture of excellence through continuing personal and professional growth.